Limitations of voriconazole include emerging CYP51 mutations (e.g., TR34/L98H), linked to treatment failure in prolonged use, and compromised bioavailability in gastrointestinal dysfunction (e.g., chemotherapy-induced mucositis), necessitating therapeutic drug monitoring. The gene discussed is CYP51A1; the disease is mucositis.